紫杉醇(Paclitaxel)是近十年来发现的化学结构新颖,作用机理独特的新型抗肿瘤药物。它在癌细胞分裂时能与细胞微管蛋白结合,促进细胞中微管聚合,抑制其解聚,使细胞有丝分裂受到阻断,从而抑制肿瘤生长。1988年美国开始Ⅱ期临床试验。1992年12月美国食品药品管理局(FDA)正式批准紫杉醇用于转移性卵巢癌的治疗,以后又批准可用于治疗转移性 Paclitaxel is a new anticancer drug with novel chemical structure and unique mechanism of action discovered in recent ten years. It can be combined with the cell tubulin when the cancer cell divides, promotes the microtubule polymerization in the cell, inhibits its disaggregation, blocks the cell mitosis, thus inhibits the tumor growth. In 1988 the United States began Phase Ⅱ clinical trials. December 1992 US Food and Drug Administration (FDA) formally approved paclitaxel for the treatment of metastatic ovarian cancer, and later approved for the treatment of metastatic